arrow_back Back to App

Alpha-1 Antitrypsin Deficiency Home Treatment: New Medicare Coverage

This act aims to improve access to home treatment for Alpha-1 Antitrypsin Deficiency for individuals covered by Medicare. It means that the costs of intravenous administration kits and nursing services related to this treatment will be covered, potentially reducing financial burden and improving quality of life for patients.
Key points
Medicare Part B will cover Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) provided at home by qualified suppliers.
The act ensures coverage for intravenous administration kits and up to 2 hours of nursing services for home therapy administration.
These changes will take effect on January 1, 2025, allowing time for preparation for the new rules.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_4438
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27]
Process start date: 2023-06-30
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

John W. Walsh Alpha-1 Home Infusion Act of 2023

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_4438.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2023-06-30.

What are the main provisions?

Key points include:

  • Medicare Part B will cover Alpha-1 Antitrypsin Deficiency treatment (augmentation therapy) provided at home by qualified suppliers.
  • The act ensures coverage for intravenous administration kits and up to 2 hours of nursing services for home therapy administration.
  • These changes will take effect on January 1, 2025, allowing time for preparation for the new rules.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Salazar, Maria Elvira [R-FL-27].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Benefits